ARTICLE | Clinical News
Naloxone nasal spray regulatory update
July 28, 2014 7:00 AM UTC
AntiOp said FDA granted Fast Track designation for AntiOp’s naloxone nasal spray to aid in the reversal of opioid overdose. The product is in Phase I testing. AntiOp’s nasal formulation is a prefilled, unit-dose, disposable delivery system designed to administer naloxone across the nasal mucosal membrane for absorption. ...